Key result
Intra-arterial tirofiban during EVT linked to ~2.9-fold higher odds of symptomatic ICH.
Cohort (n=218)
Odds Ratio: 2.9 (95% CI 1.1–7.5)
Absolute Event Rate: 14.6% vs 5.7%
p-value: p=0.027
Background and Purpose— This study aimed to explore safety of tirofiban in endovascular treatment of acute ischemic stroke. Methods— Two hundred eighteen ischemic stroke patients receiving endovascular thrombectomy were prospectively recruited, with 94 treated with intra-arterial tirofiban and 124 were not. The 2 groups were compared in terms of symptomatic intracranial hemorrhage (ICH) and fatal ICH rate by the χ 2 test and logistic regression. Results— Patients treated with tirofiban compared with those without tirofiban had significantly higher rate of symptomatic ICH (14.6% versus 5.7%; P =0.027) and fatal ICH (8.8% versus 1.6%; P =0.014). Tirofiban-treated patients had increased odds of symptomatic ICH by 2.9-fold (95% CI, 1.1–7.5), and odds of fatal ICH increased by 5.9-fold (95% CI, 1.2–28.4). Conclusions— Tirofiban treatment increases risk of major ICH after endovascular thrombectomy for acute ischemic stroke in this nonrandomized study.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2018) conducted a cohort in Acute ischemic stroke (n=218). Intra-arterial tirofiban vs. No tirofiban was evaluated on Symptomatic intracranial hemorrhage (ICH) (OR 2.9, 95% CI 1.1-7.5, p=0.027). Intra-arterial tirofiban during endovascular thrombectomy for acute ischemic stroke significantly increased the odds of symptomatic intracranial hemorrhage (14.6% vs 5.7%; OR 2.9; 95% CI 1.1-7.5).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: